Pharmacist-Led Continuous Glucose Monitoring for Prediabetes
Redefining Prediabetes Care: Pharmacist-Led Continuous Glucose Monitoring to Drive Lifestyle Change
University of South Florida
40 participants
Jun 1, 2026
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to determine if a pharmacist-led program involving continuous glucose monitoring (CGM) improves glucose control and health behavior in people with prediabetes. The main questions it aims to answer are: 1. Determine impact of pharmacist-led CGM on glycemic control in people with prediabetes. Researchers will compare change in hemoglobin A1c at 12 weeks with pharmacist-led CGM versus a historical cohort of subjects with prediabetes receiving no CGM. The investigators will also assess change in CGM-derived glycemic metrics from baseline to end of the CGM wear period in the intervention group. 2. Evaluate impact of pharmacist-led CGM on health behavior change in people with prediabetes in the intervention group. Participants will be asked to complete the Summary of Diabetes Self-Care Activities Measure (SDSCA) and 36-Item Short Form Health Survey (SF-36) at baseline, at the end of week 4, and at the end of the study so that researchers can measure the effects in the intervention group on health behavior change.
Eligibility
Inclusion Criteria4
- adults 18-70 years of age
- prediabetes (HbA1c 5.7-6.4%)
- compatible smartphone with the Dexcom Stelo sensor system
- have not have worn a CGM in the last 6 months prior to enrollment
Exclusion Criteria8
- any of the following forms of diabetes: type 1 diabetes, type 2 diabetes, monogenic diabetes, cystic fibrosis-related diabetes, post- transplant diabetes, latent autoimmune diabetes
- problematic hypoglycemia
- pregnant, or planning to become pregnant during the study time frame
- currently receiving or planned to receive dialysis during the study time frame - current use of systemic steroids for any condition
- a known allergy to medical grade adhesives,
- use of any CGM device in the past 6 months
- history of a diagnosed eating disorder
- current use of a second-generation antipsychotic at the time of consent (aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone). - - subjects lacking capacity to provide informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Subjects included in the intervention group will be recruited from the USF Health Department of Family Medicine. Each subject will be enrolled for 12 weeks. The CGM sensors are worn on the upper arm and changed every 15 days.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07529366